Minimal residual disease in multiple myeloma: bringing the bench to the bedside

Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium

(2014) Ola Landgren et al.   AMERICAN JOURNAL OF HEMATOLOGY

Next-generation sequencing of peripheral B-lineage cells pinpoints the circulating clonotypic cell pool in multiple myeloma

(2014) B. Thiele et al.   BLOOD

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

(2014) J. Martinez-Lopez et al.   BLOOD

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

(2014) Jens G. Lohr et al.   CANCER CELL

Minimal Residual Disease: What Are the Minimum Requirements?

(2014) Mark Roschewski et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved long-term survival in multiple myeloma up to the age of 80 years

(2014) S Y Kristinsson et al.   LEUKEMIA

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

(2014) Niccolo Bolli et al.   Nature Communications

Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding

(2013) Y. K. Shim et al.   BLOOD

Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity

(2013) A. Flanders et al.   BLOOD

Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study

(2013) Joaquin Martinez-Lopez et al.   BRITISH JOURNAL OF HAEMATOLOGY

Deep Sequencing Reveals Myeloma Cells in Peripheral Blood in Majority of Multiple Myeloma Patients

(2013) Ravi Vij et al.   Clinical Lymphoma Myeloma & Leukemia

Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma

(2013) Prashant Kapoor et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

(2013) Andy C. Rawstron et al.   JOURNAL OF CLINICAL ONCOLOGY

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

(2013) N Puig et al.   LEUKEMIA

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

(2013) S K Kumar et al.   LEUKEMIA

Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders

(2013) M Ladetto et al.   LEUKEMIA

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

(2013) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer

(2013) Sarah-Jane Dawson et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

(2012) A. J. Jakubowiak et al.   BLOOD

Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia

(2012) M. Faham et al.   BLOOD

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

(2012) J J M van Dongen et al.   LEUKEMIA

Phenotypic Detection of Clonotypic B Cells in Multiple Myeloma by Specific Immunoglobulin Ligands Reveals their Rarity in Multiple Myeloma

(2012) Martin Trepel et al.   PLoS One

The Level of Minimal Residual Disease in the Bone Marrow of Patients with Multiple Myeloma before High-Dose Therapy and Autologous Blood Stem Cell Transplantation Is an Independent Predictive Parameter

(2011) Mark Korthals et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

(2011) B. Paiva et al.   BLOOD

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation

(2011) E. Zamagni et al.   BLOOD

Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma

(2011) Bruno Paiva et al.   JOURNAL OF CLINICAL ONCOLOGY

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment

(2011) A. C. Logan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma

(2010) Sham Mailankody et al.   LEUKEMIA & LYMPHOMA

Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study

(2009) Ingemar Turesson et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of newly diagnosed multiple myeloma: advances in current therapy

(2009) Shaji Kumar   MEDICAL ONCOLOGY

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

(2008) B. Paiva et al.   BLOOD

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

(2008) A. C. Rawstron et al.   HAEMATOLOGICA

Multiple Myeloma Cancer Stem Cells

(2008) Carol Ann Huff et al.   JOURNAL OF CLINICAL ONCOLOGY